Study #2024-0072
A singlearm, openlabel, multicenter phase 2 study to evaluate the efficacy and safety of Taletrectinib in patients with advanced or metastatic ROS1 positive NSCLC and other solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Taletrectinib
Description
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Small Cell Lung Cancer
Study phase:
Phase II
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-866-253-6411
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.